Mismatch repair protein expression defects in endometrioid endometrial adenocarcinoma

Objectives: Endometrioid endometrial carcinoma (EEC) is the sentinel cancer in over half female patients with heritable mismatch repair (MMR) mutations as part of Lynch syndrome. Immunohistochemical testing for tumoural MMR-protein expression is the primary screening test identifying cases potentially harbouring familial cancer syndrome-related mutations and is also a predictive biomarker for immune-checkpoint blockade response. Methods: Following Data Protection and Ethical clearance by the University of Malta, 200 EEC cases were retrospectively identified and categorized into three arms: 151 cases above age 50 at diagnosis, 49 cases at or below age 50 at diagnosis and 30 controls with benign endometrial tissue sampling. H&E case slides were re-examined by an independent pathologist to confirm the diagnosis and identify the block best representing the tumour. Four new slides per case were recut and immunohistochemistry performed for MLH1, PMS2, MSH2, and MSH6 proteins. Protein expression was analysed semiquantitatively using Allred scoring. Results: 31% of the overall EEC cases were deficient for one or more MMR-proteins. Dual loss of the MLH1-PMS2 protein heterodimer was the most common deficiency, occurring in 24.5% of cases. Loss of MSH2-MSH6 protein expression represented 3.2% of MMR-deficient cases. Well differentiated tumours had a 76.5% proficiency rate as opposed to grade 2/3 disease with 53.2% and 52.9% proficiency rate respectively. There was no significant difference in MMR status when age 50 was used as a hypothetical testing threshold. After correcting for tumour grade, MLH1 and PMS2 expression was shown to be negatively correlated with age-at-diagnosis while MSH6 expression was positively correlated. Conclusion: Reflex MMR proficiency testing of all EEC cases is advisable, as using age 50 as a testing threshold would have missed 82.3% of MMR deficient cases. Prospective evidence is required to clarify the role semi-quantitative scoring plays in MMR status interpretation and patient management in the ever-evolving field of targeted therapeutics.

Mismatch repair; MutS homolog 2; MutS homolog 6; MutL homolog 1; PMS-2 protein; Endometrial neoplasms; Neoplastic syndromes

[1] Cancer incidence for common cancers. Cancerresearchuk.org. 2020. Available at: https://www.cancerresearchuk.org/health-p rofessional/cancer-statistics/incidence/common-cancers-compa red (Accessed: 05 May 2020).

[2] Uterine cancer incidence by stage. Cancerresearchuk.org. 2020. Available at: http://www.cancerresearchuk.org/sites/default/fil es/cstream-node/inc_by_stage_uterine.pdf (Accessed: 05 May 2020).

[3] Warthin AS. Heredity with reference to carcinoma: as shown by the study of the cases examined in the pathological laboratory of the university of Michigan, 1895–1913. Archives of Internal Medicine. 1913; 12: 546–555.

[4] Peltomaki P, Aaltonen L, Sistonen P, Pylkkanen L, Mecklin J, Jarvinen H, et al. Genetic mapping of a locus predisposing to human colorectal cancer. Science. 1993; 260: 810–812.

[5] Lindblom A, Tannergård P, Werelius B, Nordenskjöld M. Genetic mapping of a second locus predisposing to hereditary nonpolyposis colon cancer. Nature Genetics. 1993; 5: 279–282.

[6] Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature. 1993; 363: 558–561.

[7] Aaltonen LA, Peltomäki P, Leach FS, Sistonen P, Pylkkänen L, Mecklin JP, et al. Clues to the pathogenesis of familial colorectal cancer. Science. 1993; 260: 812–816.

[8] Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science. 1993; 260: 816–819.

[9] de la Chapelle A. Microsatellite instability. The New England Journal of Medicine. 2003; 349: 209–210.

[10] Zhao P, Li L, Jiang X, Li Q. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti- PD-1/PD-L1 immunotherapy efficacy. Journal of Hematology & Oncology. 2019; 12: 54.

[11] Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecologic Oncology. 1983; 15: 10–17.

[12] Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013; 497: 67–73.

[13] Salvesen HB, MacDonald N, Ryan A, Iversen OE, Jacobs IJ, Akslen LA, et al. Methylation of hMLH1 in a population-based series of endometrial carcinomas. Clinical Cancer Research. 2000; 6: 3607– 3613.

[14] Long Q, Peng Y, Tang Z, Wu C. Role of endometrial cancer abnormal MMR protein in screening Lynch-syndrome families. International Journal of Clinical and Experimental Pathology. 2014; 7: 7297–7303.

[15] Buchanan DD, Tan YY, Walsh MD, Clendenning M, Metcalf AM, Ferguson K, et al. Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing. Journal of Clinical Oncology. 2014; 32: 90–100.

[16] Mills AM, Liou S, Ford JM, Berek JS, Pai RK, Longacre TA. Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer. The American Journal of Surgical Pathology. 2014; 38: 1501–1509.

[17] Kim J, Kong J, Yang W, Cho H, Chay DB, Hong S, et al. Clinicopathologic significance of MMR immunohistochemistry and MLH1 methylation test in women with endometrial cancer. Gynecologic Oncology. 2017; 145: 43.

[18] Kim J, Kong JK, Yang W, Cho H, Chay DB, Lee BH, et al. DNA mismatch repair protein immunohistochemistry and MLH1 promotor methylation testing for practical molecular classification and the prediction of prognosis in endometrial cancer. Cancers. 2018; 10: 279.

[19] Haruma T, Nagasaka T, Nakamura K, Haraga J, Nyuya A, Nishida T, et al. Clinical impact of endometrial cancer stratified by genetic mutational profiles, POLE mutation, and microsatellite instability. PLoS ONE. 2018; 13: e0195655.

[20] Saeki H, Hlaing MT, Horimoto Y, Kajino K, Ohtsuji N, Fujino K, et al. Usefulness of immunohistochemistry for mismatch repair protein and microsatellite instability examination in adenocarcinoma and background endometrium of sporadic endometrial cancer cases. Journal of Obstetrics and Gynaecology Research. 2019; 45: 2037–2042.

[21] Puangsricharoen P, Manchana T, Ariyasriwatana C, Triratanachat S. Immunohistochemistry staining for the mismatch repair proteins in endometrial cancer patients. Thai Journal of Obstetrics and Gynaecology. 2020; 28: 79–85.

[22] Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, Marini C, et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2013; 24: vi33–vi38.

[23] Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Research. 1996; 56: 3087–3090.

[24] Brown R, Hirst GL, Gallagher WM, McIlwrath AJ, Margison GP, van der Zee AG, et al. HMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene. 1997; 15: 45–52.

[25] Drummond JT, Anthoney A, Brown R, Modrich P. Cisplatin and adriamycin resistance are associated with MutLα and mismatch repair deficiency in an ovarian tumor cell line. Journal of Biological Chemistry. 1996; 271: 19645–19648.

[26] Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehmé A, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Research. 1997; 56: 4881–4886.

[27] Amin A, Buratovich MA. New platinum and ruthenium complexes-the latest class of potential chemotherapeutic drugs-a review of recent developments in the field. Mini Reviews in Medicinal Chemistry. 2009; 9: 1489–1503.

[28] Yoshioka K, Yoshioka Y, Hsieh P. ATR kinase activation mediated by MutSα and MutLα in response to cytotoxic O6-methylguanine adducts. Molecular Cell. 2006; 22: 501–510.

[29] Li Z, Pearlman AH, Hsieh P. DNA mismatch repair and the DNA damage response. DNA Repair. 2016; 38: 94–101.

[30] Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. The New England Journal of Medicine. 2015; 372: 2509–2520.

[31] KEYTRUDA® (pembrolizumab) approval. Highlights of prescribing information. 2019. Available at: https://www.accessdata.fda.g ov/drugsatfda_docs/label/2019/125514s040lbl.pdf (Accessed: 10 July 2020).

[32] Kernel Networks Inc. Simultaneous review decisions for pembrolizumab plus lenvatinib in Australia, Canada and US. Case Medical Research. 2019. Available at: http://dx.doi.org/10. 31525/cmr-1d27113 (Accessed: 09 May 2020).

[33] Makker V, Rasco D, Vogelzang NJ, Brose MS, Cohn AL, Mier J, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, openlabel, single-arm, phase 2 trial. The Lancet Oncology. 2019; 20: 711–718.

[34] Hou Y, Nitta H, Parwani AV, Li Z. PD-L1 and CD8 are associated with deficient mismatch repair status in triple-negative and her2positive breast cancers. Human Pathology. 2019; 86: 108–114.

[35] Fraune C, Burandt E, Simon R, Hube-Magg C, Makrypidi-Fraune G, Kluth M, et al. MMR Deficiency is homogeneous in pancreatic carcinoma and associated with high density of Cd8-positive lymphocytes. Annals of Surgical Oncology. 2020; 27: 3997–4006.

[36] Uterus cancers. Malta national cancer registry. 2014. Available at: http://health.gov.mt/en/dhir/Documents/Cancer/2014/uter us%202014.pdf (Accessed: 09 May 2020).

[37] Uterus cancers. Deputyprimeminister.gov.mt. 2020. Available at: https://deputyprimeminister.gov.mt/en/dhir/Documents/Can cer/2020/cancers%20pdfs/Uterus%20body_2017.pdf (Accessed: 09 May 2020).

[38] Chen W, Swanson BJ, Frankel WL. Molecular genetics of microsatellite-unstable colorectal cancer for pathologists. Diagnostic Pathology. 2017; 12: 24.

[39] Mensenkamp AR, Vogelaar IP, van Zelst-Stams WAG, Goossens M, Ouchene H, Hendriks-Cornelissen SJB, et al. Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatchrepair deficiency in Lynch syndrome-like tumors. Gastroenterology. 2014; 146: 643–646.e8.

[40] Goldblum J, Lamps L, McKenney J, Myers J. Guidelines for handling of most common and important surgical specimens. In: Rosai and Ackerman’s Surgical Pathology (pp. 2581–2636). Elsevier. 2011.

[41] Alturkustani M, Al-Maghrabi H. The effects of delayed formalin fixation on endometrial pathology in hysterectomy specimens. International Journal of Clinical and Experimental Pathology. 2019; 12: 3134–3139.

[42] Houghton JP, Roddy S, Carroll S, McCluggage WG. A simple method for the prevention of endometrial autolysis in hysterectomy specimens. Journal of Clinical Pathology. 2004; 57: 332–333.

[43] Fadhil W, Ilyas M. Immunostaining for mismatch repair (MMR) protein expression in colorectal cancer is better and easier to interpret when performed on diagnostic biopsies. Histopathology. 2012; 60: 653–655.

[44] Li X, Yao X, Wang Y, Hu F, Wang F, Jiang L, et al. MLH1 promoter methylation frequency in colorectal cancer patients and related clinicopathological and molecular features. PLoS ONE. 2013; 8: e59064.

[45] Mangold E, Pagenstecher C, Friedl W, Fischer H, MerkelbachBruse S, Ohlendorf M, et al. Tumours from MSH2 mutation carriers show loss of MSH2 expression but many tumours from MLH1 mutation carriers exhibit weak positive MLH1 staining. The Journal of Pathology. 2005; 207: 385–395.

[46] Shia J, Klimstra DS, Nafa K, Offit K, Guillem JG, Markowitz AJ, et al. Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms. The American Journal of Surgical Pathology. 2005; 29: 96–104.

[47] Barrow E, Jagger E, Brierley J, Wallace A, Evans G, Hill J, et al. Semiquantitative assessment of immunohistochemistry for mismatch repair proteins in Lynch syndrome. Histopathology. 2010; 56: 331–344.

[48] Sari A, Pollett A, Eiriksson LR, Lumsden-Johanson B, Van de Laar E, Kazerouni H, et al. Interobserver agreement for mismatch repair protein immunohistochemistry in endometrial and nonserous, nonmucinous ovarian carcinomas. The American Journal of Surgical Pathology. 2019; 43: 591–600.

[49] Stormorken AT, Bowitz-Lothe IM, Norèn T, Kure E, Aase S, Wijnen J, et al. Immunohistochemistry identifies carriers of mismatch repair gene defects causing hereditary nonpolyposis colorectal cancer. Journal of Clinical Oncology. 2005; 23: 4705–4712.

[50] Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. The Journal of Molecular Diagnostics. 2008; 10: 293–300.

[51] Watkins JC, Nucci MR, Ritterhouse LL, Howitt BE, Sholl LM. Unusual mismatch repair immunohistochemical patterns in endometrial carcinoma. The American Journal of Surgical Pathology. 2016; 40: 909–916.

[52] Boland CR, Shike M. Report from the jerusalem workshop on lynch syndrome-hereditary nonpolyposis colorectal cancer. Gastroenterology. 2010; 139: e1–e5.

[53] Pearlman R, Markow M, Knight D, Chen W, Arnold CA, Pritchard CC, et al. Two-stain immunohistochemical screening for Lynch syndrome in colorectal cancer may fail to detect mismatch repair deficiency. Modern Pathology. 2018; 31: 1891–1900.

[54] Nakagawa H, Nuovo GJ, Zervos EE, Martin EW Jr, Salovaara R, Aaltonen LA, et al. Age-related hypermethylation of the 5’ region of MLH1 in normal colonic mucosa is associated with microsatellite-unstable colorectal cancer development. Cancer Research. 2001; 61: 6991–6995.

[55] Crucianelli F, Tricarico R, Turchetti D, Gorelli G, Gensini F, Sestini R, et al. MLH1 constitutional and somatic methylation in patients with MLH1 negative tumors fulfilling the revised Bethesda criteria. Epigenetics. 2014; 9: 1431–1438.

[56] Crum CP, Nucci MR, Granter SR, Howitt BE, Parast MM, Boyd T, et al. Diagnostic gynecologic and obstetric pathology. 3rd ed. Philadelphia, PA: Elsevier - Health Sciences Division. 2017.